PremiumRatingsLexicon Pharmaceuticals: Strong Financials and Promising R&D Pipeline Justify Buy Rating Lexicon Pharmaceuticals Reports Promising Start to 2025 Lexicon reports Q1 EPS (7c), consensus (10c) PremiumThe FlyLargest borrow rate increases among liquid names Largest borrow rate increases among liquid names Largest borrow rate increases among liquid names PremiumWeekend UpdatesVistra, Ardelyx, Zscaler, Lexicon, Arista: Trending by Analysts Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges Lexicon price target lowered to $6 from $10 at Piper Sandler 
